Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
BNT162b2
Booster vaccination
Inactivated COVID-19 vaccine
SARS-CoV-2 antibody
School-aged children
Journal
Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
29
06
2022
revised:
21
09
2022
accepted:
28
09
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
A primary series of 2-dose SARS-CoV-2 vaccines based on an ancestral strain generate inadequate neutralizing antibodies against the SARS-CoV-2 Omicron variant. This study aimed to describe the immune response from giving healthy school-aged children who previously received 2 inactivated vaccines an mRNA BNT162b2 booster. Healthy children aged 5-11 years who received 2 doses of CoronaVac or Covilo were enrolled and received 10 µg BNT162b2 intramuscularly. Neutralizing antibody against Omicron variant was measured at pre-booster and 14-21 days post-booster by surrogate virus neutralization test (sVNT, %inhibition) and pseudovirus neutralization test (pVNT, ID From April to May 2022, 59 children with a mean age (SD) of 8.5 years (1.7) were enrolled: 20 CoronaVac and 39 Covilo recipients. The median interval from the primary series was 49 days (IQR 33-51). After booster, the geometric means (GMs) of sVNT and pVNT were 72.2 %inhibition (95 %CI 67.2-77.6) and 499 (95 %CI 399-624), respectively. The proportion of children with sVNT against Omicron strain ≥68 %inhibition increased from none to 70.2 %. The geometric mean ratio (GMR) of sVNT and pVNT compared with a parallel cohort were 4.3 and 12.2, respectively. The GMR of sVNT and pVNT between children who received booster dose at >6-week interval were 1.2 (95 %CI 1.1-1.3). and 1.8 (95 %CI 1.2-2.7) compared with 4-6 weeks interval. A regimen of 2-dose of inactivated vaccine followed by BNT162b2 booster dose elicited high neutralizing antibody against the Omicron variants in healthy school-aged children.
Sections du résumé
Background
UNASSIGNED
A primary series of 2-dose SARS-CoV-2 vaccines based on an ancestral strain generate inadequate neutralizing antibodies against the SARS-CoV-2 Omicron variant. This study aimed to describe the immune response from giving healthy school-aged children who previously received 2 inactivated vaccines an mRNA BNT162b2 booster.
Methods
UNASSIGNED
Healthy children aged 5-11 years who received 2 doses of CoronaVac or Covilo were enrolled and received 10 µg BNT162b2 intramuscularly. Neutralizing antibody against Omicron variant was measured at pre-booster and 14-21 days post-booster by surrogate virus neutralization test (sVNT, %inhibition) and pseudovirus neutralization test (pVNT, ID
Results
UNASSIGNED
From April to May 2022, 59 children with a mean age (SD) of 8.5 years (1.7) were enrolled: 20 CoronaVac and 39 Covilo recipients. The median interval from the primary series was 49 days (IQR 33-51). After booster, the geometric means (GMs) of sVNT and pVNT were 72.2 %inhibition (95 %CI 67.2-77.6) and 499 (95 %CI 399-624), respectively. The proportion of children with sVNT against Omicron strain ≥68 %inhibition increased from none to 70.2 %. The geometric mean ratio (GMR) of sVNT and pVNT compared with a parallel cohort were 4.3 and 12.2, respectively. The GMR of sVNT and pVNT between children who received booster dose at >6-week interval were 1.2 (95 %CI 1.1-1.3). and 1.8 (95 %CI 1.2-2.7) compared with 4-6 weeks interval.
Conclusion
UNASSIGNED
A regimen of 2-dose of inactivated vaccine followed by BNT162b2 booster dose elicited high neutralizing antibody against the Omicron variants in healthy school-aged children.
Identifiants
pubmed: 36213592
doi: 10.1016/j.jvacx.2022.100221
pii: S2590-1362(22)00081-X
pmc: PMC9531410
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100221Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
N Engl J Med. 2022 May 19;386(20):1899-1909
pubmed: 35353976
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428
pubmed: 35298453
J Infect Dis. 2022 Mar 10;:
pubmed: 35267040
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Nat Commun. 2022 May 13;13(1):2670
pubmed: 35562366
Vaccines (Basel). 2022 Apr 19;10(5):
pubmed: 35632395
Lancet Reg Health Am. 2022 Sep;13:100316
pubmed: 35872665
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826
pubmed: 34915551
Vaccines (Basel). 2022 Apr 03;10(4):
pubmed: 35455305
Vaccines (Basel). 2021 Aug 03;9(8):
pubmed: 34451975
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):352-358
pubmed: 35239634
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Lancet. 2022 Feb 5;399(10324):521-529
pubmed: 35074136
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Methods Protoc. 2018 Jan 22;1(1):
pubmed: 31164554
Nat Med. 2022 Mar;28(3):481-485
pubmed: 35051990
Lancet Glob Health. 2022 Jun;10(6):e798-e806
pubmed: 35472300
Hematol Transfus Cell Ther. 2021 Apr-Jun;43(2):212-213
pubmed: 33778377
Vaccines (Basel). 2022 May 16;10(5):
pubmed: 35632541
N Engl J Med. 2022 Jan 6;386(1):35-46
pubmed: 34752019
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Nat Commun. 2022 Aug 13;13(1):4756
pubmed: 35963844